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Abstract objectives Children younger than 12 months of age are eligible for childhood vaccines through the
public health system in Guinea-Bissau. To limit open vial wastage, a restrictive vial opening policy
has been implemented; 10-dose measles vaccine vials are only opened if six or more children aged 9–
11 months are present at the vaccination post. Consequently, mothers who bring their child for
measles vaccination can be told to return another day. We aimed to describe the household
experience and estimate household costs of seeking measles vaccination in rural Guinea-Bissau.
methods Within a national sample of village clusters under demographic surveillance, we
interviewed mothers of children aged 9–21 months about their experience with seeking measles
vaccination. From information about time and money spent, we calculated household costs of seeking
measles vaccination.
results We interviewed mothers of 1308 children of whom 1043 (80%) had sought measles
vaccination at least once. Measles vaccination coverage was 70% (910/1308). Coverage decreased
with increasing distance to the health centre. On average, mothers who had taken their child for
vaccination took their child 1.4 times. Mean costs of achieving 70% coverage were 2.04 USD (SD
3.86) per child taken for vaccination. Half of the mothers spent more than 2 h seeking vaccination
and 11% spent money on transportation.
conclusions We found several indications of missed opportunities for measles vaccination resulting
in suboptimal coverage. The household costs comprised 3.3% of the average monthly income and
should be taken into account when assessing the costs of delivering vaccinations.
keywords measles vaccine, Guinea-Bissau, household costs, missed opportunities
Introduction
In low-income countries, WHO recommends Bacille Cal-
mette-Guerin (BCG) vaccine at birth followed by three
doses of pentavalent vaccine (diphtheria-tetanus-pertussis-
hepatitis B-Haemophilus influenzae type b) and oral polio
vaccine (OPV) at 6, 10 and 14 weeks of age. The first
dose of measles vaccine (MV) is recommended at
9 months of age [1]. In Guinea-Bissau in West Africa,
routine vaccinations are provided free of charge at health
centres and through outreach services.
Although measles mortality has dropped by an esti-
mated 75% between 2001 and 2014 [2] , measles was
still the leading cause of vaccine-preventable deaths in
children in 2016 [3]. The World Health Assembly has
committed to increase MV coverage to at least 90%
nationally and regional measles elimination goals have
been set. In 2020, measles elimination should be achieved
in at least five WHO regions [2]. However, with an MV
coverage of 69% in 2014 in Guinea-Bissau [4], the
national MV coverage goal of 90% is far from within
reach. In Guinea-Bissau, here are two major barriers at
the health centre for getting vaccinated. First, targets for
low vaccine wastage have entailed a restriction on open-
ing of multidose vials of live vaccines. The lyophilised
live MV comes in 10-dose vials, which have to be used
within 6 h after diluting the vaccine. Focus on vaccine
wastage has increased; while the MV target wastage rate
in Guinea-Bissau was 15% in 2010, it was 11% in 2014
[5]. Consequently, a MV vial is not opened unless a
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sufficient number of children due to be vaccinated are
present [6]. Also, the performance evaluation of the Gui-
nean vaccination programme is based on vaccination cov-
erage at 12 months of age. The WHO/UNICEF Joint
Reporting Form instructs the Ministry of Health to report
vaccination coverage among infants [7], and thus, vacci-
nation of children older than 12 months does not count
in the statistics [6]. As a result, the Expanded Programme
of Immunization (EPI) in Guinea-Bissau has increasingly
focused on infants and children older than 12 months are
no longer entitled to vaccines [6].
Consequently, a MV vial is not opened unless at least
six 9- to 11-month-old children are present to receive
MV [6]. This implies that mothers can take their children
for vaccination several times before succeeding in having
their child vaccinated, and for some mothers, this delay
entails that her child becomes too old to receive MV [6].
The costs incurred by the household of seeking vaccina-
tions could be substantial as mothers often have long dis-
tances to the health centre, long waiting times and due to
the restrictive vial opening policy may be told to return
another day.
Household costs of seeking routine vaccination has to
our knowledge not been studied in a low-income setting.
We describe the experience with seeking MV and esti-
mate household costs of seeking MV under the restrictive
MV policy in Guinea-Bissau.
Methods
The Bandim Health Project (BHP) follows 182 clusters of
approximately 100 women of fertile age and their under-
five children in a health and demographic surveillance
system in rural Guinea-Bissau. The clusters are visited
every 6 months by BHP mobile teams, registering new
pregnancies and children and collecting information
aimed at assessing the health of children under survey,
including vaccination status. Information on vaccinations
is obtained from the child’s health card. A nurse accom-
panies the mobile teams and offers routine vaccines to
children with missing vaccinations. Global Positioning
System (GPS) coordinates of the villages and the closest
health centre have been collected.
In 2011, the BHP initiated a cluster-randomised trial
(MVEPI) to evaluate the effects of the restrictive MV pol-
icy. Villages were cluster-randomised to follow the
national MV policy; MV between 9 and 11 months of
age and only if 6 or more eligible children were present
(the control arm) or to receive MV if the child was
unvaccinated and between 9 and 35 months of age
regardless of number of children present (the intervention
arm). The trial outcome measures are mortality,
morbidity and growth. We took advantage of the trial
set-up to collect information on experiences with seeking
MV among all children being screened for enrolment.
Data collection
Data collection for this study took place between Febru-
ary 2013 and September 2014 in the regions where the
MVEPI trial was implemented, that is Oio, Gabu, Bafata,
Quinara, Tombali, Bijagos Islands (Bubaque/Bolama). No
MV shortages occurred during this period [8]. The heavy
rains from June to November damage the already poorly
conditioned roads in Guinea-Bissau, increasing trans-
portation time, or even making access to some villages
impossible. To ensure that the seasonal variation in trans-
portation time was captured, all villages were visited at
least twice, once during the rainy season and once during
the dry season.
We interviewed all mothers/guardians of children aged
9–14 months in their home. Children in this age group
were too young to have received MV at the previous visit
to the village 6 months earlier. We specified that we were
interested in obtaining information about the vaccine
‘given in the back’ (only MV is administered at this site
in Guinea-Bissau) to avoid confusion with other vaccines.
We asked the mother how many times she had sought
MV, transportation costs and time spent on seeking MV.
If the mother was not present at the first visit, another
interview was attempted at the next visit 6 months later,
when the child was 15–21 months old.
Children enrolled in the MVEPI control arm were
interviewed again at the subsequent visit 6 months later
as they may have sought vaccination at the health centre.
Data analyses
Measles vaccine coverage was assessed among children
screened for enrolment in MVEPI and whose health card
was inspected on the day of the interview or at a subse-
quent visit. We calculated MV coverage as the proportion
of children already vaccinated according to the vaccina-
tion card. Some mothers reported taking their child zero
times for MV, although the child was already measles-
vaccinated due to outreach. We re-coded these mothers
to have gone once for vaccination (n = 128). For the
analyses of transportation time and costs, it was assumed
that these mothers did not go to the health facility and
thus incurred no costs.
Costs of transportation were recorded in West-African
Francs (CFA) and converted to US dollars using the 2013
average exchange rate of one USD to 478.7 CFA
(www.oanda.com). Time spent seeking vaccination was
© 2016 John Wiley & Sons Ltd 13
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recorded as hours from leaving home until returning
home.
Coverage of other vaccines by 12 months of age was
assessed for children screened for enrolment in MVEPI
with a health card seen between 12 and 23 months of
age. A child was considered otherwise fully vaccinated if
he/she had received one dose of BCG, three doses of pen-
tavalent vaccine and three doses of OPV by 12 months of
age. We also assessed coverage of the third dose of pen-
tavalent vaccine as this vaccine has no vial opening
restriction. We calculated the distance from the GPS
mapped village centre to the nearest health centre.
We calculated the costs of seeking MV for each child
individually. The costs of time spent on seeking vaccina-
tion, were valued according to the average salary across
all sectors in the economy. Based on data on yearly earn-
ings from 36 countries, Knight et al.[9] constructed a
regression model with GNI per capita as the independent
variable. For Guinea-Bissau, this model estimated average
monthly earnings as 61 USD in 2011. We converted this
to 0.35 USD per hour, assuming 176 working hours per
month (22 working days*8 h a day). Costs of seeking
vaccination for each child was estimated by multiplying
number of hours spent on seeking MV by the average
hourly earning, adding costs of transportation, if any,
and multiplying by the number of times vaccination was
sought.
Results
Study population
A total of 2298 children aged 9–21 were eligible for
screening for enrolment in MVEPI and therefore eligible
for interview on experiences with MV. Of these, 1503
mothers were present for interview (65%). In 32% of vis-
its, the mother was not present, and for 3% of the visits,
the field assistant provided no reason for not interview-
ing.
We included 1308 children with seen health cards and
complete information on number of times MV was
sought (Figure 1). Of the responses with complete infor-
mation, 70% (910/1308) were measles vaccinated. A
total of 1043 (80%) of children were taken for MV at
least once.
Factors associated with seeking measles vaccination
Twenty-nine percentage (95% CI: 25-33%) (142/490) of
children aged 9-11 months had not been taken for MV,
55% (51–59%) (270/490) were taken for MV once, and
16% (13-19%) (78/490) were taken twice or more for
MV (range; 2–4 times) (Figure 2). Coverage was 59%
(55–63%) (287/490).
Among children aged 12–21 months, 67% (64–70%)
(548/818) were taken for MV once and 18% (15–21%)
(147/818) twice or more (range; 2–6 times). Coverage in
children 12–21 months was 76% (73–79%) (623/818).
Among measles-unvaccinated children, 34% (29–39%)
(135/398) of mothers had attempted to get their child
vaccinated (Figure 2); the proportion was higher in chil-
dren who were 12 months or older (Figure S1). 9%
(6–12%) of children not yet MV had been taken for MV
3–6 times (Figure 2). The number of times varied by
region (Figure S2). The proportion of children taken for
MV increased with age (Figure 3). Thus, 35% (27–43%)
(53/150) of <10-month-old children were not taken for
MV yet, while the proportion was 11% (6–16%) among
children aged 14–21 months (Figure 3).
Coverage was lower, and children were taken fewer
times for MV among those living >5 km from a health
centre than among children living within a 2 km radius
(P < 0.01) (Figure S3). Thus, 76% (73–80%) (441/580)
of mothers living >5 km away took their child for vacci-
nation and coverage was 65% (61–69%). In comparison,
83% (80–87%) (363/437) living ≤2 km away were taken
for MV with a coverage of 75% (71–79%) (Figure S3).
Overall, 80% (78–82%) (1043/1308) of the inter-
viewed mothers took their child for MV at least once;
excluding children who were vaccinated by outreach
(n = 128) the proportion was 77% (75–80%) (916/
1180).
Costs of seeking vaccination under the national measles
vaccine policy
Of 910 children (86% (84–88%), 782 already measles
vaccinated had been taken for MV at least once. This
was 134/398 (34% (29–39%)) among children not
measles vaccinated. Thus, a total of 916 children were
taken for MV. Among mothers who took their child for
MV, 99/916 (11% (9–13%)) spent money on transporta-
tion (Table 1); on average 1.05 USD (SD 1.14). A larger
proportion of mothers in Quinara and Tombali spent
money on transport relative to other regions. Time spent
on seeking vaccination was missing in 5% of the inter-
views (43/916); 44% (380/873) of mothers spent ≤2 h
(range 0–2 h) and 5% (44/873) spent more than 8 h
(range 9–36 h) (Table 2). The regional variation was sub-
stantial with 68% (61–75%) (91/183) of mothers in
Gabu spending ≤2 h (range; 0–2 h) vs. 19% (12–26%)
(25/132) in Tombali.
The majority of measles-unvaccinated children (96%
(381/398)) were enrolled in the MVEPI study and 32%
14 © 2016 John Wiley & Sons Ltd
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(121/381) of these reported having sought MV; 66/121
(55%) mothers said they were told to come back another
day or that not enough children were present to open a
vial; 226/381 children were enrolled in the control arm
of MVEPI and had not yet been vaccinated at the inter-
view day. We re-interviewed 96/226 (42%) at the
5% (3-7%) 7% (5-9%) 5% (4-6%) 9% (6-12%)
11%
(8-14%)
11%
(9-13%)
14%
(12-16%) 6% (4-8%)
55%
(51-59%)
67%
(54-70%)
81%
(78-84%)
19%
(15-23%)
29%
(25-33%)
15%
(13-17%)
0%
66%
(61-71%)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
≤12 months >12 months Already MV Not MV
By age 
3+ times 2 times 1 time 0 times
n = 490 n = 818 n = 910 n = 398
By MV status
Figure 2 Number of times the mother
went to the health centre for vaccination
by age of child and by MV status,
overall.
2298 children residing in the BHP study
villages, aged 9-21 months and eligible for
interview
735 (32%) mothers absent for
interview
40 (3%) missing reason for no
interview
1503 (65%) available for interview
83 (6%) did not have their vaccination
card seen
112 (7%) had a missing value in number
of times to health center
1308 with seen
vaccination card
910 (70%) children already
measles vaccinated at
interview
398 (30%) not measles
vaccinated at interview
381 (96%) included in MVEPI
226 (59%) included in MVEPI
control arm
94 (42%) re-interviewed
155 (41%) included in MVEPI
intervention arm
Figure 1 Interview participant flow.
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subsequent visit 6 months later. MV coverage at the sec-
ond interview was 77% (74/96), but 88% said they took
their child for MV.
The mean cost was 1.33 USD (SD 1.43) per time a
child was taken for MV (Table 2). On average, mothers
took their children for MV 1.40 times – thus, 0.4 times
(equivalent to 0.53 USD) per child could have been
avoided if the staff provided MV at every opportunity.
The average costs of seeking vaccination among mothers
who took their children for MV more than once was
4.51 USD (SD 6.83) (distribution of costs in Figure S4).
The mean cost incurred by the mothers, and hence, the
mean cost of attaining a total coverage of 70% was 2.04
USD (SD 3.86) per child taken for vaccination. Strikingly,
two mothers living in Tombali and Quinara spent USD
41.7 and USD 83.5, respectively, on taking their child for
MV. The high costs were due to long transportation time
(24 and 36 h) and high transportation costs (USD 2 and
USD 8). Both took their child for MV four times.
According to our estimates, taking a child for MV
accounts for 3.3% of the estimated average monthly
income of 61 USD in Guinea-Bissau. Further, the costs of
seeking MV was equivalent to 19.4% of the annual
expenditure on health per capita of 10.5 USD in 2013
[10].
Other vaccinations and missed opportunities for measles
vaccination
Among the 1308 children, 1124 (86%) had their vaccina-
tion card inspected between 12 and 23 months of age
(Table 2). A significantly higher proportion of children
taken for MV were otherwise fully vaccinated by
12 months (89% (808/906)) than children who were not
taken for MV (69% (150/218)) (p < 0.01). Similarly, cov-
erage of the third pentavalent vaccine dose was 77% (168/
218) among children not taken for MV yet and 96% (873/
906) among children taken for MV. In addition, 35% (77/
218) of children not yet taken for MV had received a
delayed pentavalent vaccine between 9 months and age of
health card inspection. Further, 3% (27/803) of measles-
vaccinated children received a delayed pentavalent vaccine
between 9 months of age and date of measles vaccination,
while 29% (92/321) of measles-unvaccinated children
received a delayed pentavalent vaccine between 9 months
and date of health card inspection (Table 3).
Discussion
Measles vaccination coverage was 70%. Thirty-four per-
centage of children not measles-vaccinated had been
5% (2-8%) 3% (0-6%) 7% (3-11%) 8% (4-12%) 9% (5-13%) 6% (4-8%)
7% (3-11%) 11%(6-16%)
15%
(10-20%) 9% (5-13%)
12%
(7-17%) 12%(9-15%)
53%
(45-61%)
58%
(50-66%)
53%
(46-60%) 61%(54-68%)
61%
(54-68%)
71%
(67-75%)
35%
(27-43%)
28%
(21-35%)
25%
(19-31%)
22%
(16-128)
18%
(12-24%)
11%
(8-14%)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
<10 10 11 12 13 14-21
3+ times 2 times 1 time 0 times MV coverage
n = 150 n = 166 n = 174 n = 188 n = 169 n = 461
Figure 3 Number of times the mother
took her child for vaccination, by child’s
age (months) at interview.
Table 1 Transport costs for seeking measles vaccination (2013 USD)
Oio
(n = 39)
Gabu
(n = 268)
Bafata
(n = 201)
Quinara
(n = 210)
Tombali
(n = 138)
Bijagos
(n = 60)
Total
(n = 916)
Number of mothers
who paid for transport
(n (%(95% CI))
1 (3 (2
to 8))
4 (2 (0–4)) 30 (15 (10–20)) 41 (20 (15–25)) 23 (17 (11–23)) 0 (0) 99 (11 (9–13))
Mean costs of transport
(SD)*
1.26 2.78 (1.74) 1.27 (0.70) 1.60 (1.36) 1.08 (0.90) N/A 1.05 (1.14)
*Among those who paid for transport.
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taken for MV once or more (range 1–6 times) without suc-
ceeding. Nineteen percentage of children already measles-
vaccinated had been taken for MV twice or more (range
2–5 times). There were also missed MV opportunities not
captured by our data: 35% of the mothers who reported
not having taken their child for MV had received a delayed
pentavalent vaccine after 9 months of age.
On average mothers took their child for MV 1.4 times;
half of the mothers spent more than 2 h (range 2.5–36 h)
with 5% spending more than 8 h seeking MV and 11%
spent money on transportation.
The household costs of achieving a 70% MV coverage
in rural Guinea-Bissau was 2.04 USD per child taken for
MV, equivalent to 3.3% of the estimated average
monthly income and 19.4% of annual expenditure on
health per capita.
We have found no other study assessing and quantify-
ing household costs and experiences of seeking routine
MV in a low-income setting. Our estimates rely on a
large sample of 1308 children embedded in the routine
data collection of the BHP enabling us to follow children
over time and providing extra information on reasons for
not receiving MV at the health centre.
During village visits, the BHP teams see the vaccination
card of approximately 70% of the children <2 years [6]. In
the present study, 65% of the mothers of children eligible
for interview were present. As some mothers work away
from home and may not have time to take their children
for vaccination, it could be speculated that the number of
times a child was taken for MV was overestimated. How-
ever, we are more likely to have underestimated the num-
ber of times; in a study from 1998 in Guinea-Bissau,
mother’s recall of the child being measles-vaccinated was
an accurate marker of measles vaccination status, although
mothers’ recall slightly underestimated coverage [11]. This
is also supported by 128 mothers who reported not having
taken their child for MV even though the child had
received MV; and 35% of the mothers who had not taken
their child for MV, received a delayed pentavalent vaccine
after 9 months of age, indicating that they had taken their
child for vaccination.
Although the low MV coverage in Guinea-Bissau is
likely to be a consequence of the restrictive MV policy,
health-seeking behaviour also plays a role: coverage of
the third dose of pentavalent vaccine was higher among
children taken for MV than in children not taken for
MV. This may reflect that mothers who did not take their
child for MV were less likely to take their child for vacci-
nation in general. Several factors have been associated
with completeness and timeliness of vaccinations in low-
income countries [12]: Among others, out-of-hospital
births, no reminder about the next vaccination visit, low
socio-economic status, several children in the household
and mothers working outside the home [12] play a role.
Despite barriers to seek vaccination, our results show
that many mothers took their child for MV without suc-
ceeding and some instead received a missing pentavalent
vaccine.
We found a measles vaccination coverage of 59%
among 9- to 11-month-old children for whom we saw
the vaccination card. Thus, we may have overestimated
measles vaccination coverage as children without a vacci-
nation card or who travel and therefore do not have their
card inspected, may have lower coverage [6].
We did not assess the household costs of vaccination
for other vaccines; we would expect that the costs of
seeking vaccines in multidose vials which can be used
over 4 weeks (e.g. pentavalent and OPV) or single-dose
vials (rotavirus and pneumococcal vaccines) to corre-
spond to the cost of a single visit, while the household
costs of obtaining other lyophilised vaccines (BCG and
yellow fever) would be higher as these are also subject to
restrictions on vial opening.
We observed that measles vaccination coverage
decreased with distance to the health centre. Nonetheless,
76% of interviewed caretakers living >5 km from the
health centre took their child for MV. However, coverage
was only 65%, indicating that health centre policy plays
a role in vaccination success. Among children included in
the MVEPI control arm, we found that at least 55% of
missed opportunities could be directly related to restric-
tive MV policy (the mother reported being told to come
back another day). As there were no MV shortages dur-
ing the data collection period [8] and 96% of children
taken for MV were vaccinated with pentavalent vaccine,
it seems unlikely that vaccination practices or health
worker unavailability explains the low coverage.
Missed opportunities due to restrictive vial opening
have also been seen in Turkey where one reason for not
vaccinating children was that there were no open vials at
the village health centres [13]. In an older literature
review on missed opportunities for vaccination, BCG and
MV vials were less frequently opened compared with
Diphtheria-Tetanus-Pertussis (DTP) and OPV due to fear
of vaccine wastage[14].
In general, there are two strategies to reduce open vial
wastage of lyophilised vaccines; reduce vial size or
increase number of participants in vaccination sessions
[15]. The cost per MV dose varies substantially by vial
size. In 2013 the price per dose in a 10-dose MV vial
was 0.24 USD [16]. Prices for single-dose vials have not
been quoted by UNICEF since 2003, where a single-dose
vial was 0.77 USD [16]. Hence, the cost of vaccinating
children is less if more than three doses are used from
18 © 2016 John Wiley & Sons Ltd
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each 10-dose MV vial, than using only single-dose vials.
In a simulation study of MV vial size in Niger, reducing
vial size from 10 dose to single dose increased the costs
per dose as well as the total volume of vials and cold
chain; increasing costs of vaccine administration and
waste disposal, which far outweighed the costs saved
from decrease in wasted doses [17]. Thus, if coverage is
to be increased, the restrictive vial opening policy must
be abolished. Even if a 10-dose vial was used only for
one child, the cost of measles vaccinating a child is still
only slightly more expensive than one dose of pentavalent
vaccine, which is between 1.85 and 2.11 USD in a 10-
dose vial [18]. In addition to protecting against measles
infection, MV also has a profound impact on survival,
reducing child mortality by up to 50% in vaccinated
compared to MV-unvaccinated children [19]. This is far
more than can be explained by prevention of measles
deaths [20–22], indicating that MV has beneficial non-
specific effects on the immune system [19] in addition to
its measles-preventive effects.
Increasing session sizes is the current policy to reduce
open vial wastage in Guinea-Bissau. However, as the pre-
sent study shows, this policy affects vaccination coverage
and shifts the cost burden to households. Some innova-
tive actions are being developed to increase session sizes.
In a randomized controlled trial from Zimbabwe, vacci-
nation coverage was significantly higher among mothers
who received a reminder to get their child vaccinated
than among mothers who did not receive any reminders
[23]. Further, introducing a second dose of routine MV
as recommended by the WHO [24] could increase overall
MV coverage and reduce open vial wastage as more
doses would be required in each session.
While proper monitoring of wastage and reasons for
wastage are essential for an efficient delivery of vaccines, it
is imperative that wastage targets do not compromise cov-
erage. The WHO and Gavi provide recommended wastage
targets when applying for vaccine support, but it is the
country itself which defines wastage targets suitable for its
setting [25]. Although Gavi has a 40% indicative maxi-
mum wastage target for MV, Guinea-Bissau has specified
its wastage targets of 11–15% for MV [5]. These very low
wastage targets are also specified for other African coun-
tries [26] and may indicate that restrictions on vial opening
take place in several other countries as well. It is not Gavi/
WHO policy to restrict measles vial opening or limiting the
age criteria [24]. Although vaccination of children older
than 12 months is seen as wastage, as only coverage of
children <12 months of age is reported to WHO/UNICEF
[7], we found that some children still receive MV after
12 months. However, the vaccination coverage rate is
lower than among children younger than 12 months and
enforcing a restrictive vial opening policy is therefore the
main reason for the many missed opportunities among
children taken for MV.
Conclusions
The restrictive MV vial opening policy and restrictive MV
age policy affect coverage and result in costs for mothers
in rural Guinea-Bissau. Household costs of seeking MV
constituted 3.3% of the estimated average monthly income
and 19.4% of the average per capita health expenditure
and should be taken into account when assessing the costs
of delivering vaccines. A quarter of children older than
12 months were measles-unvaccinated. To increase MV
coverage, it is imperative that both the restrictive vial pol-
icy and the restrictive age policy are abandoned. Taking
the low cost of MV and the marked beneficial effects asso-
ciated with MV into consideration, we recommend that a
10-dose MV be reclassified as a ‘1+ dose vial’, which is
opened for a single child, irrespective of age, but which
can be extended to vaccinate up to 10 children.
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